Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis
Copyright © 2018 Elsevier Ltd. All rights reserved..
BACKGROUND: Metabolic abnormalities and peripheral inflammation have been increasingly reported in patients at the onset of psychosis and associated with important physical health disorders and increased mortality. However, the impact of an abnormal metabolic-inflammatory status on the psychiatric outcome of these patients has not yet been investigated.
OBJECTIVES: The aims of this study were 1) to explore whether, in a sample of patients at their first episode of psychosis (FEP), an overall metabolic-inflammatory status may be measured, by combining metabolic and inflammatory variables in metabolic-inflammatory factors; 2) to explore the association between these factors and clinical outcome at 1-year follow-up (FU), in terms of symptoms severity and treatment response.
METHODS: In this longitudinal study we recruited 42 FEP patients and 46 healthy controls (HC) matched with patients for age, gender and ethnicity. At baseline (T1) we measured high sensitivity C-reactive protein (hsCRP) as biomarker of inflammation, and body mass index (BMI), lipid profile and gluco-metabolic parameters (glycated hemoglobin (HbA1c) and fasting glucose) as metabolic variables. A principal component analysis (PCA) was then used to reduce the dimensionality of the dataset accounting for both inflammation and metabolic status. In FEP patients, we assessed symptoms severity at T1 and at 1-year FU (T2) as well as treatment response to antipsychotics at T2.
RESULTS: at T1, FEP showed higher HbA1c (p = 0.034), triglycerides (TG) (p = 0.045) and BMI (p = 0.026) than HC. PCA identified 3 factors: factor 1 accounting for hsCRP, TG and BMI, factor 2 accounting for LDL and cholesterol, and factor 3 accounting for fasting glucose and HbA1c. Factor 1 was associated with T1 negative symptoms severity (p = 0.021) and predicted T2 positive (p = 0.004) and overall symptoms severity (0.001), as well as general psychopathology (p < 0.001) and T2 treatment response (p = 0.007).
CONCLUSION: In this sample of FEP patients, inflammation and metabolism, closely correlated at the onset of psychosis, proved to play a key role as predictors of the clinical course of psychosis when combined in a single factor. These findings offer an important potential target for early screening and interventions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Psychoneuroendocrinology - 99(2019) vom: 05. Jan., Seite 145-153 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nettis, Maria Antonietta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.05.2019 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.psyneuen.2018.09.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288794842 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288794842 | ||
| 003 | DE-627 | ||
| 005 | 20231225061126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.psyneuen.2018.09.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0962.xml |
| 035 | |a (DE-627)NLM288794842 | ||
| 035 | |a (NLM)30243054 | ||
| 035 | |a (PII)S0306-4530(18)30398-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nettis, Maria Antonietta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.05.2019 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Metabolic abnormalities and peripheral inflammation have been increasingly reported in patients at the onset of psychosis and associated with important physical health disorders and increased mortality. However, the impact of an abnormal metabolic-inflammatory status on the psychiatric outcome of these patients has not yet been investigated | ||
| 520 | |a OBJECTIVES: The aims of this study were 1) to explore whether, in a sample of patients at their first episode of psychosis (FEP), an overall metabolic-inflammatory status may be measured, by combining metabolic and inflammatory variables in metabolic-inflammatory factors; 2) to explore the association between these factors and clinical outcome at 1-year follow-up (FU), in terms of symptoms severity and treatment response | ||
| 520 | |a METHODS: In this longitudinal study we recruited 42 FEP patients and 46 healthy controls (HC) matched with patients for age, gender and ethnicity. At baseline (T1) we measured high sensitivity C-reactive protein (hsCRP) as biomarker of inflammation, and body mass index (BMI), lipid profile and gluco-metabolic parameters (glycated hemoglobin (HbA1c) and fasting glucose) as metabolic variables. A principal component analysis (PCA) was then used to reduce the dimensionality of the dataset accounting for both inflammation and metabolic status. In FEP patients, we assessed symptoms severity at T1 and at 1-year FU (T2) as well as treatment response to antipsychotics at T2 | ||
| 520 | |a RESULTS: at T1, FEP showed higher HbA1c (p = 0.034), triglycerides (TG) (p = 0.045) and BMI (p = 0.026) than HC. PCA identified 3 factors: factor 1 accounting for hsCRP, TG and BMI, factor 2 accounting for LDL and cholesterol, and factor 3 accounting for fasting glucose and HbA1c. Factor 1 was associated with T1 negative symptoms severity (p = 0.021) and predicted T2 positive (p = 0.004) and overall symptoms severity (0.001), as well as general psychopathology (p < 0.001) and T2 treatment response (p = 0.007) | ||
| 520 | |a CONCLUSION: In this sample of FEP patients, inflammation and metabolism, closely correlated at the onset of psychosis, proved to play a key role as predictors of the clinical course of psychosis when combined in a single factor. These findings offer an important potential target for early screening and interventions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BMI | |
| 650 | 4 | |a Clinical outcome | |
| 650 | 4 | |a First episode psychosis | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Metabolism | |
| 650 | 4 | |a Predictor | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 650 | 7 | |a hemoglobin A1c protein, human |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 700 | 1 | |a Pergola, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Kolliakou, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connor, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Bonaccorso, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a David, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Gaughran, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Di Forti, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Robin M |e verfasserin |4 aut | |
| 700 | 1 | |a Marques, Tiago Reis |e verfasserin |4 aut | |
| 700 | 1 | |a Blasi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Bertolino, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pariante, Carmine M |e verfasserin |4 aut | |
| 700 | 1 | |a Dazzan, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Mondelli, Valeria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychoneuroendocrinology |d 1993 |g 99(2019) vom: 05. Jan., Seite 145-153 |w (DE-627)NLM000122548 |x 1873-3360 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2019 |g day:05 |g month:01 |g pages:145-153 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.psyneuen.2018.09.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2019 |b 05 |c 01 |h 145-153 | ||